Apr 112011

Establishing mediastinal spread of non-small cell lung cancer (N2-3 disease) precludes surgery and worsens prognosis; whether PET-CT imaging can improve overall accuracy or safely prevent mediastinoscopies is still unknown. Fischer et al re-heat the data from their 2009 NEJM randomized trial in Denmark, with EUS-FNA and mediastinoscopy on 189 NSCLC patients, in which they concluded that the half who first got PET-CTs had fewer futile thoracotomies. Here, they report: 1) PET-CT improved diagnostic accuracy, mainly in peripheral tumors, with the gold standard of consensus N staging; 2) Size of lymph nodes on imaging was extremely important: For mediastinal LNs >=10 mm, PET had a 15% false-negative rate, but for normal-sized LNs, the rate was only 4%. They recommend A) PET-CT for all new diagnoses of NSCLC; B) straight-to-resection for people with normal-sized mediastinal LNs that are PET-negative; C) enlarged LNs need invasive sampling regardless of PET uptake, as do PET-positive LNs. Accuracy of mediastinal sampling techniques (mediastinoscopy / EUS / EBUS FNA) vary by local availability and expertise. Thorax 2011;66:294-300.

Get our weekly email update, and explore our library of practice updates and review articles.

PulmCCM is an independent publication not affiliated with or endorsed by any organization, society or journal referenced on the website. (Terms of Use | Privacy Policy)


Finding PET-CT’s place in mediastinal staging of NSCLC